Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. DOCS
stocks logo

DOCS

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Financial AI Agent
Financial AI Agent

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2026Q3
FY2026Q4
FY2027Q1
181.63M
+7.72%
0.447
-0.67%
150.34M
+8.71%
0.322
-15.3%
160.96M
+10.31%
0.370
+2.78%
Estimates Revision
The market is revising Upward the revenue expectations for Doximity, Inc. (DOCS) for FY2026, with the revenue forecasts being adjusted by 1.76% over the past three months. During the same period, the stock price has changed by -39.49%.
Revenue Estimates for FY2026
Revise Upward
up Image
+1.76%
In Past 3 Month
EPS Estimates for FY2026
Revise Upward
up Image
+3.5%
In Past 3 Month
Stock Price
Go Down
down Image
-39.49%
In Past 3 Month
Wall Street analysts forecast DOCS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DOCS is 68.46 USD with a low forecast of 55.00 USD and a high forecast of 82.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
15 Analyst Rating
Wall Street analysts forecast DOCS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DOCS is 68.46 USD with a low forecast of 55.00 USD and a high forecast of 82.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Buy
6 Hold
2 Sell
Moderate Buy
Current: 43.850
sliders
Low
55.00
Averages
68.46
High
82.00
Current: 43.850
sliders
Low
55.00
Averages
68.46
High
82.00
Barclays
Glen Santangelo
Overweight
initiated
$63
2025-12-08
New
Reason
Barclays
Glen Santangelo
Price Target
$63
2025-12-08
New
initiated
Overweight
Reason
Barclays analyst Glen Santangelo initiated coverage of Doximity with an Overweight rating and $63 price target. The firm started the U.S healthcare technology and distribution industry with a neutral view. Barclays is most bullish on the drug distributors and has a more mixed view of the dental and healthcare information technology sub-sectors.
Raymond James
Outperform -> Strong Buy
upgrade
$75 -> $65
2025-11-21
Reason
Raymond James
Price Target
$75 -> $65
2025-11-21
upgrade
Outperform -> Strong Buy
Reason
Raymond James upgraded Doximity to Strong Buy from Outperform with a price target of $65, down from $75. The stock's risk/reward is "too compelling to ignore" following the post-earnings selloff, the analyst tells investors in a research note. The firm thinks Doximity's long-term growth visibility is improving. Raymond James says the recent pullback has the shares at a discount to the vertical software group that is "too great to ignore."
BMO Capital
Market Perform
initiated
$55
2025-11-12
Reason
BMO Capital
Price Target
$55
2025-11-12
initiated
Market Perform
Reason
BMO Capital initiated coverage of Doximity with a Market Perform rating and $55 price target. Doximity's strong clinician engagement through its social and workflow platform enhances its appeal as a marketing tool for pharmaceutical companies, the analyst tells investors in a research note. While growth opportunities remain through user expansion and monetization, the current valuation suggests much of this potential is already reflected in the share price, BMO says.
Canaccord
Hold
downgrade
$67 -> $58
2025-11-10
Reason
Canaccord
Price Target
$67 -> $58
2025-11-10
downgrade
Hold
Reason
Canaccord lowered the firm's price target on Doximity to $58 from $67 and keeps a Hold rating on the shares. The firm said they posted a strong beat and the previously implied 2H FY'26 guidance was essentially maintained which seemed to drive the shares lower. Canaccord said the conservative stance comes from potential DTC advertising and drug pricing changes that have the possibility to drive Pharma management to alter budgets in remaining months of calendar 2025 and plans for calendar 2026.
Mizuho
Neutral
maintain
$60 -> $62
2025-11-10
Reason
Mizuho
Price Target
$60 -> $62
2025-11-10
maintain
Neutral
Reason
Mizuho raised the firm's price target on Doximity to $62 from $60 and keeps a Neutral rating on the shares. The firm upped estimates post the earnings report citing revenue and margin strength.
Evercore ISI
Elizabeth Anderson
Outperform
downgrade
$81 -> $70
2025-11-07
Reason
Evercore ISI
Elizabeth Anderson
Price Target
$81 -> $70
2025-11-07
downgrade
Outperform
Reason
Evercore ISI analyst Elizabeth Anderson lowered the firm's price target on Doximity to $70 from $81 and keeps an Outperform rating on the shares. The company reported a "strong" Q2, but pull-forward tempers second half growth, the analyst tells investors.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Doximity Inc (DOCS.N) is 27.70, compared to its 5-year average forward P/E of 57.06. For a more detailed relative valuation and DCF analysis to assess Doximity Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average PE
57.06
Current PE
27.70
Overvalued PE
103.48
Undervalued PE
10.64

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
37.68
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
66.89
Undervalued EV/EBITDA
8.47

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
17.50
Current PS
0.00
Overvalued PS
26.66
Undervalued PS
8.33
Intellectia AI SwingMax
Intellectia AI SwingMax

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

DOCS News & Events

Events Timeline

(ET)
2025-11-06
16:14:32
Doximity reports Q3 revenue between $180M and $181M, slightly below consensus of $180.7M
select
2025-11-06
16:13:53
Doximity Announces Q2 Earnings Per Share of 45 Cents, Exceeding Consensus Estimate of 38 Cents
select
2025-11-06
14:27:07
Prominent Companies Set to Report After Market Close
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
7.5
12-12Globenewswire
Ventripoint Partners with Nisg̱a'a Valley to Deliver Advanced Cardiac Imaging
  • Innovative Collaboration Model: Ventripoint's partnership with Nisg̱a'a Valley Health Authority establishes a model that transforms standard 2D ultrasound images into MRI-level 3D models using the VMS+ system, significantly reducing cardiac assessment costs and eliminating the need for MRI scans, thereby enhancing healthcare accessibility for remote and Indigenous communities.
  • Technology Deployment Plan: The collaboration employs a hub-and-spoke design where a central hub with advanced cardiac capabilities supports local healthcare providers in remote communities, enabling rapid transmission of ultrasound results for expert interpretation, with plans to expand to more First Nations communities and remote areas globally, promoting equity in healthcare services.
  • Executive Appointment: Ventripoint appointed David Swetlow as CFO in October, bringing over 15 years of senior management experience from high-growth medical technology firms, which is viewed as a key step in executing a refreshed commercial strategy aimed at driving market adoption and revenue growth.
  • Business Model Transformation: The company announced a shift to a Device-as-a-Service subscription model, with management believing this change will shorten sales cycles and build recurring revenue, while qualified leads from Europe and North America are increasing, indicating market recognition of its technology.
[object Object]
Preview
7.5
12-12Newsfilter
Ventripoint Partners with Nisg̱a'a for Advanced Cardiac Imaging in Remote Communities
  • Innovative Collaboration: Ventripoint's partnership with Nisg̱a'a Valley Health Authority establishes a model that transforms standard 2D ultrasound images into MRI-level 3D models using the VMS+ system, significantly reducing costs and eliminating delays associated with MRI scans for cardiac assessments.
  • Strategic Accessibility: This collaboration employs a hub-and-spoke model where a central hub with advanced cardiac capabilities supports healthcare services in remote and Indigenous communities, ensuring access to advanced diagnostics for all, thereby enhancing healthcare accessibility.
  • Global Expansion Potential: Future phases aim to extend this model to additional First Nations communities across Canada and remote areas worldwide, including the Amazon, Africa, and India, highlighting Ventripoint's potential for global market expansion in cardiac imaging.
  • Executive Appointment: Ventripoint appointed David Swetlow as CFO in October, leveraging his extensive experience in high-growth medical technology to drive market adoption and revenue growth across international markets.
[object Object]
Preview
3.5
12-11NASDAQ.COM
Hims & Hers Enhances Its Technology-Based Customized Virtual Healthcare Services

  • Hims & Hers Health Innovations: Hims & Hers is enhancing its technology-driven digital health platform with new features like Labs for holistic testing, personalized hormonal treatments for menopause, and exclusive access to branded oral testosterone for men’s health, while expanding geographically into Canada.

  • Teladoc Health Developments: Teladoc Health is advancing its digital health platform by integrating AI and monitoring tools, recently adding an AI-enabled workplace-safety module to improve real-time threat detection and intervention.

  • Doximity's AI Integration: Doximity is enhancing its clinician platform with AI-powered tools, reporting record utilization of its AI suite, and acquiring Pathway to deepen its clinical-reference capabilities.

  • Market Performance and Future Outlook: Hims & Hers shares have increased by 56.7% year-to-date, with a positive earnings forecast for 2025, while the article discusses the potential for significant wealth creation in the next wave of AI investments.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Doximity Inc (DOCS) stock price today?

The current price of DOCS is 43.85 USD — it has decreased -0.63 % in the last trading day.

arrow icon

What is Doximity Inc (DOCS)'s business?

Doximity, Inc. provides a digital platform for the United States medical professionals. It offers marketing, hiring, and workflow solutions to pharmaceutical manufacturers, health systems, medical recruiting firms, and other healthcare companies. Its marketing solutions enable its pharmaceutical and health system customers to get the right content, services, and peer connections to the right medical professionals through a variety of modules. Its hiring solutions provide digital recruiting capabilities to health systems and medical recruiting firms, enabling them to identify, connect with, and hire from its network of both active and passive medical professional candidates, who might otherwise be missed through traditional recruiting channels. Its workflow solutions include its telehealth, on-call scheduling, and AI-powered workflow tools, are designed to help clinicians streamline their clinical workflow, reduce their administrative burden, and connect with patients and colleagues.

arrow icon

What is the price predicton of DOCS Stock?

Wall Street analysts forecast DOCS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DOCS is 68.46 USD with a low forecast of 55.00 USD and a high forecast of 82.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Doximity Inc (DOCS)'s revenue for the last quarter?

Doximity Inc revenue for the last quarter amounts to 168.53M USD, increased 23.16 % YoY.

arrow icon

What is Doximity Inc (DOCS)'s earnings per share (EPS) for the last quarter?

Doximity Inc. EPS for the last quarter amounts to 0.31 USD, increased 40.91 % YoY.

arrow icon

What changes have occurred in the market's expectations for Doximity Inc (DOCS)'s fundamentals?

The market is revising Upward the revenue expectations for Doximity, Inc. (DOCS) for FY2026, with the revenue forecasts being adjusted by 1.76% over the past three months. During the same period, the stock price has changed by -39.49%.
arrow icon

How many employees does Doximity Inc (DOCS). have?

Doximity Inc (DOCS) has 830 emplpoyees as of December 13 2025.

arrow icon

What is Doximity Inc (DOCS) market cap?

Today DOCS has the market capitalization of 8.26B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free